UK licences ‘milestone’ treatment for ovarian cancer

Organisation: Position: Deadline Date: Location:

A pill which has the potential to buy an extra 16 months of life for women with ovarian cancer has been dubbed a “milestone” treatment, after it was licensed for use in the UK. The Independent reports that the once-daily pill Niraparib is part of a new class of cancer drugs, and quadruples the time it takes for cancer to return after chemotherapy.

Clinical trials found that in women with an inherited defect in the BRCA gene, which plays a key role in suppressing the formation of tumours, time to relapse increased from 5.5 months to 21 months. In women without this mutation, time to relapse improved to a lesser extent, but was double compared to chemotherapy alone.

The report says while the drug can now be bought and prescribed in the UK, it isn’t yet available on the National Health Service (NHS). That decision, for patients in England and Wales, will be taken by the National Institute for Health and Care Excellence (Nice), which will weigh up the clinical effectiveness against the cost of any treatment.

The Scottish Medicines Consortium provides similar guidelines in Scotland.

Professor Jonathan Ledermann, from the University College London Cancer Institute and director at Cancer Research UK, said: “Niraparib is the first treatment of its class licensed to delay the progression of ovarian cancer following platinum-based chemotherapy, regardless of BRCA status.

“This represents a critical milestone in the management of ovarian cancer. Access to effective and tolerable medicines is sorely needed, and the hope is that Niraparib will be available on the NHS as quickly as possible.”

Katherine Taylor, CEO of the charity Ovarian Cancer Action, said in the report: “The outlook for women diagnosed with ovarian cancer can be bleak. Current treatment lags behind other and better-known cancers, and survival rates are low.

“Today’s news is an encouraging step in the right direction, but we now need to ensure all UK women diagnosed with recurrent platinum-sensitive ovarian cancer can benefit.

“We call upon Nice and the Scottish Medicines Consortium to approve this drug to provide more treatment options for those diagnosed with ovarian cancer – for many women this could be life changing.”

The Independent report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.